Stirling ultracold to merge with biolife solutions, the leader in gene and cell therapy bioproduction tools and services

Columbus, ohio, march 22, 2021 /prnewswire/ -- stirling ultracold, an ohio-based manufacturer and provider of the most energy efficient, sustainable ultra-low temperature (ult) biorepositories has entered into a definitive agreement to merge with biolife solutions (nasdaq: blfs), a leading provider of bioproduction products and services for the gene and cell therapy (gct) markets. stirling ultracold is backed by the ohio innovation fund (oif), with oif managing director bill baumel serving on the board, the strategic committee alongside ceo dusty tenney, and acting as the seller representative in this transaction -- oif principal faith voinovich led the reverse diligence on biolife for stirling.
BLFS Ratings Summary
BLFS Quant Ranking